Valley National Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Valley National Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-225	Closed	-$27K	–	844
2024 Q4	$27K	Hold	225	–	–	﹤0.01%	425
2024 Q3	$28K	Sell	225 -126	-36%	-$17.4K	0.01%	413
2024 Q2	$55K	Buy	351 +10	+3%	+$1.28K	0.01%	380
2024 Q1	$44K	Hold	341	–	–	0.01%	426
2023 Q4	$32K	Sell	341 -103	-23%	-$9.88K	0.01%	474
2023 Q3	$54K	Sell	444 -44	-9%	-$4.97K	0.01%	376
2023 Q2	$56K	Buy	488 +9	+2%	+$1.16K	0.01%	374
2023 Q1	$61K	Buy	479 +143	+43%	+$18.6K	0.01%	365
2022 Q4	$40K	Hold	336	–	–	0.01%	407
2022 Q3	$39K	Hold	336	–	–	0.01%	402
2022 Q2	$27K	Hold	336	–	–	0.01%	434
2022 Q1	$26K	Hold	336	–	–	0.01%	473
2021 Q4	$30K	Hold	336	–	–	0.01%	445
2021 Q3	$31K	Hold	336	–	–	0.01%	406
2021 Q2	$26K	Sell	336 -1,684	-83%	-$128K	﹤0.01%	444
2021 Q1	$151K	Buy	+2,020	New	+$186K	0.03%	236

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Valley National Advisers's SRPT Position: Q1 2025 in Review

Valley National Advisers sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 225 shares — an estimated $27K sold.

Valley National Advisers first reported a position in SRPT in Q1 2021 and held it in 16 quarters. The position peaked at $151K in Q1 2021. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Valley National Advisers reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Valley National Advisers sold 225 Sarepta Therapeutics shares in Q1 2025, an estimated $27K.
Valley National Advisers first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 16 quarters.
Valley National Advisers's Sarepta Therapeutics position peaked at $151K in Q1 2021.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Valley National Advisers's 13F filing for Q1 2025, filed 25 Apr 2025.